Vyvanse meets major depressive disorder endpoint

Shire plc (LSE:SHP; NASDAQ:SHPGY) said Vyvanse lisdexamfetamine as an adjunctive therapy met the primary endpoint vs. placebo in the Phase II SPD489-203 trial to treat major depressive disorder (MDD)....